The management of hypertensive crises: A clinical review

Clinica Terapeutica

Volumn 160, Issue 2, 2009, Pages 151-157

  Pergolini, M S ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CAPTOPRIL; CLONIDINE; DIAZOXIDE; ENALAPRIL; ENALAPRILAT; EPHEDRINE; ESMOLOL; FENOLDOPAM; FUROSEMIDE; GLYCERYL TRINITRATE; HYDRALAZINE; LABETALOL; LOSARTAN; METHYLDOPA; MINOXIDIL; NICARDIPINE; NIFEDIPINE; NITROPRUSSIDE SODIUM; PHENOXYBENZAMINE; PHENTOLAMINE; TRIMETAPHAN; URAPIDIL; VALSARTAN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BRADYCARDIA; BRAIN VASOSPASM; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DIZZINESS; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; ECLAMPSIA; EXCITEMENT; FETOTOXICITY; HEADACHE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTENSIVE CRISIS; HYPERURICEMIA; HYPOTENSION; HYPOTHYROIDISM; HYPOXIA; INTENSIVE CARE UNIT; LOADING DRUG DOSE; MUSCLE SPASM; MUSCLE WEAKNESS; NAUSEA; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PHEOCHROMOCYTOMA; RETINA ISCHEMIA; REVIEW; SIDE EFFECT; SWEATING; SYNCOPE; TACHYCARDIA; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UNSTABLE ANGINA PECTORIS; VOMITING; WATER RETENTION; XEROSTOMIA;

ACUTE DISEASE; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CASE MANAGEMENT; CEREBROVASCULAR DISORDERS; CHILD; CORONARY DISEASE; ECLAMPSIA; EMERGENCIES; FEMALE; HUMANS; HYPERTENSION, MALIGNANT; HYPERTENSION, RENAL; HYPERTENSIVE ENCEPHALOPATHY; INFANT, NEWBORN; INTENSIVE CARE; MALE; MONITORING, PHYSIOLOGIC; PRE-ECLAMPSIA; PREGNANCY; STREET DRUGS;

EID: 66249128928     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Kearney PM, Whelton M, Reynolds K, et al. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004;22:11-9
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020. Global Burden of Disease Study. Lancet 1997; 349:1498-504
3. Wolf-Mayer K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in six European countries, Canada, and the United States. JAMA 2003; 289:2363-9
4. Ferguson RK, Vlasses PH. How urgent is "urgent" hypertension? Arch Intern Med 1989; 149:257-8
5. Kaplan NM. Hypertensive Crises. In: Kaplan's NM Clinical Hypertension,-9th Italian Edition. Milan: Lippincott Williams &Wilkins, 2006; 311-24
6. Varon J, Marik PE. Clinical review: the management of hypertensive crises. Crit Care 2003; 7:374-84
7. Calhoun DA, Oparil S. Treatment of hypertensive crisis. N Engl J Med 1990; 323:1177-83
8. Kaplan NM. Management of hypertensive emergencies. Lancet 1994; 344:1335-8
9. Elliott WJ. Hypertensive emergencies. Crit Care Clin 2001; 17:435-51
10. Houston MC. Pathophysiology, clinical aspects, and treatment of hypertensive crises. Prog Cardiovasc Dis 1989; 32:99-148
11. Hypertension in pregnancy. AGOC Technical Bulletinl996, 219
12. Abroug F, Boujdaria R, Nouira S, et al. HELLP syndrome: incidence and maternal-foetal outcome - a prospective study. Intensive Care Med 1992; 18:274-7
13. Muller FB, Sealey JE, Case BD, et al. The captopril test for identifying renovascular disease in hypertensive patients. Am J Med 1986; 80(4):633-44
14. Varon J, Marik PE. The diagnosis and management of hypertensive crises. Chest 2000; 118:214-27
15. Lip GYH, Beevers M, Beevers DG. Complications and survival of 315 patients with malignant-phase hypertension. J Hypertens 1995; 13:915-24
16. Lip GYH, Beevers M, Beevers DG. The failure of malignant hypertension to decline: a survey of 24 years' experience. J Hypertens 1994; 12:1297-305
17. Biollaz J, Waeber B, Brunner HR. Hypertensive crisis treated with orally administered captopril. Eur J Clin Pharmacol 1983;25:145-9
18. Houston MC. Treatment of hypertensive emergencies and urgencies with oral clonidine loading and titration. A review. Arch Intern Med 1986; 146:586-9
19. Ghose RR. Acute management of severe hypertension with oral labetalol. Br J Clin Pharmacol 1979; 8:189S-93S
20. Atkin SH, Jaker MA, Beaty P, et al. Oral labetalol versus oral clonidine in the emergency treatment of severe hypertension. Am J Med Sci 1992; 303:9-15
21. Mc Carthy M. US NIH issues warning on nifedipine. Lancet 1995; 346:689
22. Grossman E, Messerli FH, Grodzicki T, et al: Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA 1996; 276:1328-31
23. Della Corte F, Enrichens F, Olliveri F, et al. Manuale di Medicina d'Emergenza. Mc Graw Hill Italia, II Ed. Milano, 2007; 245-54
24. th Ed. Mc Graw Hill, New York, 2004; 403
25. Friedrich JA, Butterworth JF. Sodium nitroprusside: twenty years and counting. Anesth Analg 1995; 81:152-62
26. Grossman E, Irani AN, Messerli FH. Comparative tolerability profile of hypertensive crisis treatments. Drug Safety 1998; 19:99-122
27. Lowenthal DT, Porter RS, Saris SD, et al. Clinical, pharmacology, pharmacodynamics and interactions with esmolol. Am J Cardiol 1985; 56:14F-8F
28. Mooss AN, Hilleman DE, Mohiuddin SM, et al. Safety of esmolol in patients with myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy. Ann Pharmacother 1994; 28:701-3
29. Shusterman NH. Elliot WJ, White WB. Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. Am Heart J 1993; 95:161-8
30. Bodmann KF, Troster S, Clemens R, et al. Hemodynamic profile of intravenous Fenoldopam in patients with hypertensive crisis. Clin Invest 1993; 72:60-4
31. Schillinger D. Nifedipine in hypertensive emergencies: a prospective study. J Emerg Med 1987; 5:463-73
32. Varon J, Marik PE: The diagnosis and management of hypertensive crises. Chest 2000; 118:214-27
33. Sheperd AM, Ludden TM, McNay JL, et al. Hydralazine kinetics after single and repeated oral doses. Clin Pharmacol Ther 1980; 28:804-11
34. O'Malley K, Segal JL, Israili ZH, et al. Duration of hydralazine action in hypertension. Clin Pharmacol Ther 1975; 18:581-6
35. Hirschl MM. Guidelines for the drug treatment of hypertensive crises. Drugs 1995; 50:991-1000
36. Langtry HD, Mammen GJ, Sorkine EM. Urapidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. Drugs 1989; 38:900-40
37. FontanaF, Allaria B, Brunetti B, et al. Cardiac and circulatory response to the intravenous administration of urapidil during general anaesthesia. Drugs Exp Clin Res 1990; 16:315-8